Slowing growth for its flagship drug leads to analysts' downgrades.
News & Analysis: Adamas Pharmaceuticals
ADMS earnings call for the period ending December 31, 2018.
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
Adamas Pharmaceuticals' valuation took yet another hit last month. Here's why.
Shares fall hard after the company reports good news. What's going on?
Adamas' steady march lower continued in September. Here's why.
ADMS earnings call for the period ending December 31, 2017.
Investors fret over the launch of the biotech's new Parkinson's disease drug Gocovri.
Potential competition has investors spooked.
Industry watchers are increasingly optimistic about this upstart's future.